{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:30:35Z","timestamp":1792564235759,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015728","name":"Clinical Science Research and Development","doi-asserted-by":"publisher","award":["I01 CX002015"],"award-info":[{"award-number":["I01 CX002015"]}],"id":[{"id":"10.13039\/100015728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY014801"],"award-info":[{"award-number":["P30EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018031","name":"Polsko-Amerykanska Komisja Fulbrighta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01EY026174"],"award-info":[{"award-number":["R01EY026174"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R61EY032468"],"award-info":[{"award-number":["R61EY032468"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtos.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:10:55Z","timestamp":1670260255000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7295-4936","authenticated-orcid":false,"given":"Adam","family":"Wylegala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wathanee","family":"Sripawadkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osmel P.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Al Bayyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Galor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-7181","authenticated-orcid":false,"given":"Carol L.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2022.12.002_bib1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2004.02.013","article-title":"Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors","volume":"111","author":"Shields","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib2","first-page":"109","article-title":"Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes - the 2017 J. Donald M. Gass Lecture","volume":"6","author":"Shields","year":"2017","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib3","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/tmi.12792","article-title":"Risk factors for ocular surface squamous neoplasia in Kenya: a case\u2013control study","volume":"21","author":"Gichuhi","year":"2016","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jtos.2022.12.002_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0161-6420(01)00991-5","article-title":"Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia","volume":"109","author":"Scott","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/ICU.0b013e3283622a13","article-title":"Topical chemotherapy for ocular surface squamous neoplasia","volume":"24","author":"Nanji","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40662-019-0150-5","article-title":"Update on pharmacotherapy for ocular surface squamous neoplasia","volume":"6","author":"Al Bayyat","year":"2019","journal-title":"Eye Vis"},{"key":"10.1016\/j.jtos.2022.12.002_bib7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib8","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/ICO.0b013e3182a6ea6c","article-title":"Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012","volume":"32","author":"Adler","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.12.002_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.ico.0000138834.42489.ba","article-title":"Ocular surface squamous neoplasia: a standard of care survey","volume":"24","author":"Stone","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.12.002_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0161-6420(97)30287-5","article-title":"Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia","volume":"104","author":"Tabin","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019181","article-title":"Treatment of conjunctival papilloma with topical interferon alpha-2b - case report","volume":"99","author":"Bolek","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jtos.2022.12.002_bib12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons: mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.jtos.2022.12.002_bib13","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.R700004200","article-title":"The interferons: 50 Years after their discovery, there is much more to learn","volume":"282","author":"Pestka","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtos.2022.12.002_bib14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/ICO.0000000000002615","article-title":"Ocular surface squamous neoplasia managed with primary interferon \u03b12b","volume":"40","author":"Shields","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.12.002_bib15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/0301-4738.195010","article-title":"Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients","volume":"64","author":"Kaliki","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(99)90009-X","article-title":"Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia","volume":"106","author":"Vann","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archopht.1994.01090210029007","article-title":"Regression of limbal epithelial dysplasia with topical interferon","volume":"112","author":"Maskin","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"A clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtos.2022.12.002_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003495-200666030-00005","article-title":"Mitomycin: clinical applications in ophthalmic practice","volume":"66","author":"Abraham","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jtos.2022.12.002_bib20","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","article-title":"Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications","volume":"94","author":"Russell","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","article-title":"Retrospective comparative study of topical interferon \u03b12b versus mitomycin C for primary ocular surface squamous neoplasia","volume":"36","author":"Kusumesh","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.12.002_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17469899.2017.1263567","article-title":"Diagnosis and medical management of ocular surface squamous neoplasia","volume":"12","author":"Sayed-Ahmed","year":"2017","journal-title":"Expet Rev Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtos.2022.12.002_bib24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/BF02026399","article-title":"Inhibition of tumorigenesis by topical application of low doses of vitamin A acid and fluorouracil","volume":"31","author":"Prutkin","year":"1975","journal-title":"Experientia"},{"key":"10.1016\/j.jtos.2022.12.002_bib25","article-title":"Antitumor activity of vitamin A acid and fluorouracil used in combination on the skin tumor","volume":"33","author":"Prutkin","year":"1973","journal-title":"Keratoacanthoma. Cancer Res"},{"key":"10.1016\/j.jtos.2022.12.002_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.amjoto.2003.07.002","article-title":"The effects of mitomycin C and 5-fluorouracil\/triamcinolone on fibrosis\/scar tissue formation secondary to subglottic trauma (experimental study)","volume":"26","author":"Cincik","year":"2005","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.jtos.2022.12.002_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bjo.2010.183244","article-title":"Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study","volume":"95","author":"Parrozzani","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00166683","article-title":"Topical application of 5-Fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid","volume":"64","author":"De Keizer","year":"1986","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","article-title":"Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia","volume":"199","author":"Venkateswaran","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib30","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","article-title":"Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia presented cornea society\/fall educational symposium, November 2015, Las Vegas, Nevada","volume":"123","author":"Joag","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib31","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/bjophthalmol-2016-309219","article-title":"Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study","volume":"101","author":"Parrozzani","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib32","series-title":"AJCC cancer staging manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.jtos.2022.12.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.10.012","article-title":"Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin c and interferon alpha-2b","volume":"157","author":"Besley","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib34","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.ophtha.2012.04.022","article-title":"Predictors of ocular surface squamous neoplasia recurrence after exisional surgery","volume":"119","author":"Galor","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib35","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.18240\/ijo.2019.09.09","article-title":"Factors affecting recurrence after surgical treatment in cases with ocular surface squamous neoplasia","volume":"12","author":"Mirzayev","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0161-6420(00)00389-4","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea","volume":"107","author":"Patrick Yeatts","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2022.12.002_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S9709","article-title":"5-fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea","volume":"4","author":"Al-Barrag","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib38","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00417-013-2437-x","article-title":"Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva","volume":"251","author":"Sarici","year":"2013","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bjo.86.2.168","article-title":"Squamous cell carcinoma of the conjunctiva: a series of 26 cases","volume":"86","author":"McKelvie","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib40","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/eye.2014.79","article-title":"Clinical outcome of advanced squamous cell carcinoma of the conjunctiva","volume":"28","author":"Miller","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.jtos.2022.12.002_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ceo.12377","article-title":"Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy","volume":"43","author":"Rudkin","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/archopht.123.1.109","article-title":"Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva","volume":"123","author":"Shields","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib43","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/IOP.0000000000000601","article-title":"Successful treatment of extensive squamous cell carcinoma of the conjunctiva and upper eyelid skin with topical therapy alone","volume":"33","author":"Huang","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jtos.2022.12.002_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/bjo.84.3.268","article-title":"Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil","volume":"84","author":"Midena","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/IOP.0b013e3181ac4c39","article-title":"Long-term results of topical mitomycin c 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia","volume":"25","author":"Ballalai","year":"2009","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jtos.2022.12.002_bib46","first-page":"1","article-title":"An update in the management of ocular surface squamous neoplasia","author":"Kounatidou","year":"2021","journal-title":"Expet Rev Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICO.0b013e3182523f61","article-title":"Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the american joint committee on cancer classification","volume":"32","author":"Shields","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2022.12.002_bib48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archophthalmol.2011.385","article-title":"Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on american joint committee on cancer classification","volume":"130","author":"Shah","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2022.12.002_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s40662-019-0150-5","article-title":"Update on pharmacotherapy for ocular surface squamous neoplasia","volume":"6","author":"Al Bayyat","year":"2019","journal-title":"Eye Vis"},{"key":"10.1016\/j.jtos.2022.12.002_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17469899.2017.1263567","article-title":"Diagnosis and medical management of ocular surface squamous neoplasia","volume":"12","author":"Sayed-Ahmed","year":"2017","journal-title":"Expet Rev Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422001197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422001197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:49:26Z","timestamp":1761540566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012422001197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":50,"alternative-id":["S1542012422001197"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2022.12.002","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}